Loading clinical trials...
Loading clinical trials...
A Multicenter Phase 1 Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis Using Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood
Conditions
Interventions
Orca-Q
myeloablative regimen
Start Date
March 1, 2025
Primary Completion Date
August 1, 2029
Completion Date
August 1, 2029
Last Updated
March 28, 2025
NCT07325292
NCT05748015
NCT06433765
NCT07466823
NCT04876339
NCT05344469
Multiple Sclerosis and Neuroimmunology Study Team
CONTACT
650-319-5522neuroimmunologyresearch@stanford.eduLead Sponsor
Stanford University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions